Sulfasalazine currently is the most commonly prescribed medication for inflammatory bowel disease. Insights into the pharmacokinetics, their side effects and mechanism and their possible mode of action has led to rational basis for its clinical use and the development of new related agents. This review summarizes these aspects and discusses the future role of sulfasalazine in the face of new oral preparations.